Focal therapy versus radical prostatectomy: a propensity score-matched comparison of failure-free survival
This propensity score-matched study comparing focal therapy (cryotherapy or irreversible electroporation) with radical prostatectomy for localized prostate cancer found that while radical prostatectomy offered superior failure-free survival, approximately 80% of patients treated with focal therapy remained free of radical treatment or metastasis at five years.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For men diagnosed with early-stage prostate cancer, the medical community has long faced a difficult choice between two very different paths. On one side stands the traditional approach: removing the entire prostate gland. This surgery is highly effective at eliminating the cancer but often comes with significant side effects, including changes to urinary control and sexual function. On the other side is a newer, more targeted strategy known as focal therapy. Instead of removing the whole organ, doctors use extreme cold or electrical pulses to destroy only the specific area of the prostate where the tumor is growing, leaving the healthy tissue and surrounding structures intact. The promise of focal therapy is to cure the disease while preserving a man's quality of life, but until recently, there was not enough direct evidence to know if it worked as well as the full surgery for preventing the cancer from returning or spreading.
A team of researchers from Chile and Spain set out to settle this question by comparing the long-term outcomes of these two approaches. They analyzed data from hundreds of men treated between 2014 and 2026, carefully pairing patients who received focal therapy with those who underwent radical prostatectomy. To ensure a fair comparison, they matched the men based on key factors like the aggressiveness of their cancer, their age, and the specific details of their tumors as seen on magnetic resonance imaging scans. The study focused on a specific measure called "failure-free survival," which tracks how long a patient remains free from needing further treatment or developing metastatic disease. For the men who had the full surgery, any additional treatment afterward counted as a failure. For the men who had focal therapy, a second attempt at focal treatment did not count as a failure, but moving to full surgery, radiation, or systemic drugs did.
The results, drawn from 207 matched pairs of patients, revealed a clear difference in outcomes. After an average follow-up of about three years, the men who had the full surgery were slightly less likely to experience treatment failure compared to those who had focal therapy. This gap widened over time; at the five-year mark, 88 percent of the surgery group remained free from failure, while 79 percent of the focal therapy group did. The researchers calculated that men in the focal therapy group were nearly twice as likely to require additional treatment or experience disease progression compared to their surgically treated counterparts. However, the study also highlighted that the majority of men who chose the organ-preserving route still did well. Approximately four out of five men treated with focal therapy avoided the need for radical treatment or metastasis for at least five years.
The authors emphasize that while the full surgery showed superior results in preventing failure, focal therapy remains a viable option for carefully selected patients who prioritize preserving their bodily functions. The study suggests that for these men, the trade-off is accepting a higher chance of needing further intervention later in exchange for avoiding the immediate side effects of a full prostate removal. The researchers note that their findings are based on observational data rather than a randomized clinical trial, meaning that unmeasured factors could still influence the results. Nevertheless, the data provides a clearer picture of the risks and benefits, showing that while focal therapy carries a higher risk of the cancer returning or requiring more treatment, it still offers a strong chance of long-term success for many men.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.